Rose Diagnostics Closes $1M Seed
Summary
CARLSBAD Rose Diagnostics, a developer of biomarkers designed for lung cancer diagnostics, has emerged from stealth mode after closing $1 million in seed funding from private investors.The privately held company closed the financing on June 26, according to a SEC filing. Its product uses a multiplexed dynamic predictive algorithm, sandwiched immunoassay, and lateral flow format among others unique features, according to the firm.This enables medical organizations to provide patients with better treatment options for a wide range of medical conditions, according to executives at the firm, Morris said.While the company launched last year, its currently participating in an accelerator program called Creative Destruction Lab (CDL), based in Canada.Morris, who served as mentor for that accelerator two year ago, said it felt great to be on the venture and founder side again, which involves an eight-week time commitment. He noted that he is excited for this next chapter of his career.As early as I could remember, Id always had a passion for science, said Morris. Prior to Rose Diagnostics, I was a co-founder of a number of startups that were successful, including FORGE Hydrocarbons Corp, Planet People that was sold to Rustoleum, Norigen Communications.Brouwer, the companys co-founder and chief scientific officer, spent roughly half a decade at SQI Diagnostics and brings more than fifteen years of experience working at large healthcare firms Abbott and late-stage Trinity Biotech.This is the seventh medical device startup to raise capital this year. FUNDING: $1 million WEBSITE: https://rose-dx.com/ NOTABLE: Co. is participating in Creative Destruction Labs accelerator program.